Other

Question 1

Management of acute GVHD affecting the GI tract

Answer 1

• nonabsorbable oral steroid (budesonide)
  + systemic glucocorticoid

Question 2

Management of erythrocytosis in patient with transplanted kidney

Answer 2

ACE inhibitor

Question 3

Most common mutations in CMML

Answer 3

• TET2
• SRSF2
• ASXL1

Question 4

CMML treatment

Answer 4

IF high risk, HMA bridge to transplant
IF low risk, observation
Once needing treatment HMA vs. hydrea

Question 5

Pathophysiology of cerebellar neurotoxicity with cytarabine

Answer 5

Widespread loss of purkinje fibers

Question 6

clinical benefit of early vs. delayed transplant in myeloma

Answer 6

PFS alone

Question 7

DOAC management perioperatively

Answer 7

• IF urgent surgery, reverse DOAC
• IF low/moderate bleeding risk, hold for one day before
• IF high bleeding risk, omit 2 days before

Question 8

Definition of GVHD overlap syndrome

Answer 8

simultaneous features of both chronic and acute GVHD

Question 9

Advanted of BuCy conditioning vs. BuFlu

Answer 9

• reduced time to t cell engraftment

Question 10

Burr cells on peripheral smear

Answer 10

see photo

Question 11

Burr cell differential

Answer 11

• ESRD
• Liver disease
• Pyruvate kinase deficiency

Question 12

PKD inheritance

Answer 12

autosomal recessive

Question 13

drug contrandicated with methotrexate

Answer 13

NSAIDS (reduce renal clearance)

Question 14

Site of hematopoiesis in gestation at 5/6 months

Answer 14

l*iver
bone marrow

Question 15

Peripheral smear of hereditary stomatocytosis

Answer 15

• see photo online

Question 16

Management of patient on ganciclovir for CMV and levels are uptrending

Answer 16

Continue (takes 1-2 weeks for levels to decline after starting treatment)

Question 17

Management of acquired VWF deficiency

Answer 17

recombinant VWF

Question 18

What is idecabtagene?

Answer 18

idecabtagene vicleucel (ide-cel)

Question 19

Least important antigen for hemolytic transfusion reaction

Answer 19

Lewis antigen

Question 20

Etiology of CLL patient treated with FCR and presenting with dry cough, fever, hypoxia

Answer 20

PJP oneumonia

Question 21

Other SE of IVIG to be aware of

Answer 21

aseptic meningitis

Question 22

What to do if you’ve caused hyperviscosity in LPL patient with rituximab

Answer 22

PLEX

Question 23

What to think with prolonged thrombin time

Answer 23

low fibrinogen

Question 24

Gaucher disease treatment

Answer 24

IF cytopenias or significant splenomegaly, enzyme replacement therapy

Question 25

idelalisib mechanism

Answer 25

• inhibits phosphorylated MTOR

Question 26

Letermovir SE’s

Answer 26

• AKI
• pneumonia

Question 27

Preferred systemic therapy for NLPHL

Answer 27

R-CHOP

Question 28

Sweet syndrome clinical features

Answer 28

abrupt appearance of painful, edematous, and erythematous papules, plaques, or nodules on the skin + fever + neutrophilia

Question 29

WHIM syndrome

Answer 29

Warts, Hypogammaglobulinemia, Infections, Myelokathexis
- severe neutropenia

Question 30

Management of symptomatic gastric MALT that is negative for h pylori

Answer 30

rituximab

Question 31

Management of cirrhosis from iron overload

Answer 31

liver transplantation

Question 32

Management of hemolytic anemia post liver transplant

Answer 32

• transfuse donor type RBCs

Question 33

Function of hepcidin

Answer 33

• degrades ferroportin

Question 34

Next step if patient develops thrombocytopenia post ritiximab

Answer 34

• check EBV/HCV serologies

Question 35

Second line for FL

Answer 35

• if early relapse/aggressive disease, CAR-T
• if late relapse and BR frontline, R-CHOP